Patient Recruitment Vendors for Clinical Trials: Vendor Types, Pricing Models, and the Contract Checks Before You Sign

What patient recruitment vendors actually sell, how each type charges, which obligations never leave the sponsor, and four contract checks to run after the performance questions are answered.

One analysis of the ClinicalTrials.gov results database looked at 619 trials stopped for reasons other than accumulated data. Insufficient accrual explains 57% of them, 350 trials out of 619 [1]. A single day of enrollment delay costs a sponsor roughly $500,000 in foregone sales, plus about $40,000 in direct trial costs [2].

The market built to fix that problem is organized by vendor self-description, not by what a buyer needs to compare. Six kinds of vendor answer the funnel gap in different ways, and four pricing models bill for it differently.

Refero does not run recruitment campaigns. We vet and match the clinical research marketing agencies that do, so what follows is written for the person deciding whether to hire one, and what to ask before they sign.

Patient recruitment vendor statistics at a glance

Every figure here is sourced in full at the foot of the page, to the same standard as every figure on this site.

• Insufficient accrual ended 57% of trials stopped for reasons other than accumulated data, 350 of 619 [1]
• A trial was unavailable at the patient's own institution 55.6% of the time, 21.5% of patients were ineligible, and enrollment reached 8.1% [3]
• A single delay day costs roughly $500,000 in lost sales plus $40,000 in direct trial costs [2]
• 22% of people would prefer to hear about a trial from a patient recruitment company, and 15% did [5]
• 24.9% of randomized trials in one multi-committee cohort were discontinued, most often for poor recruitment [7]

What a patient recruitment vendor is, and what it is not

A patient recruitment vendor finds, reaches, prescreens, and refers potential participants to research sites, under contract to a sponsor, CRO, or site. It is not a staffing agency for clinical research employees, and it is not the sponsor's CRO. A vendor's work moves through a funnel: awareness, prescreening, referral, first site contact, then consent and randomization at the site. Responsibility changes hands at the referral or first-contact point; from there, consent, eligibility checks, and randomization belong to the investigator. Most trials combine site-led, central, and vendor-led recruitment, so the decision is which part of the funnel to outsource, measured against the enrollment benchmarks any vendor plan has to beat.

The six vendor types and what each actually sells

Each of the six sells a different piece of the funnel, so quotes from two types price two different products. Ask which stage a vendor owns before comparing prices.

Site-network recruitment

Site management organizations recruit from patient populations they already own. Geography caps reach and therapeutic mix caps fit, so ask for the network's enrolled population in the relevant indication, not its total patient count.

Central recruitment and media agencies

Central recruitment and media agencies run sponsor-level campaigns using paid digital media, call centers, and referral portals. Referral quality decides whether that volume becomes randomizations; a loose prescreen script produces referrals sites reject.

Patient registry and database platforms

Registry platforms hold opt-in populations matched against study criteria. The catch is depth and freshness: ask how the registry was built, how many people it holds in the relevant condition, and when those records were last refreshed.

EHR and data-driven identification

EHR identification services query clinical data to flag patients likely to meet eligibility criteria before anyone contacts them. The vendor needs a lawful HIPAA pathway to the identifiable data and site or health-system IT cooperation to run the query.

Decentralized trial and eConsent platforms with recruitment modules

DCT and eConsent platforms bundle a recruitment module alongside remote-visit and electronic-consent functions. The recruitment module is usually the smaller part of a larger software purchase, and its output still feeds a site's prescreen and consent process.

CRO-bundled recruitment

Some full-service CROs sell recruitment as a line item inside a broader trial-management contract. The bundled recruitment line is often subcontracted to one of the other vendor types, and the sponsor may not know which one unless the contract requires disclosure.

What patient recruitment vendors charge: the four pricing models

The invoice structure predicts vendor behavior better than anything in a sales deck. Four models cover most contracts, each rewarding something different.

Per-referral or per-lead pricing charges a fee each time a vendor delivers a lead to a site, whatever happens next. It rewards volume and shifts risk onto the site's prescreening capacity.

Per-milestone or per-randomized pricing charges a fee only when a referral clears a set milestone, usually consent or randomization. It rewards qualification, but a vendor paid only on randomization can drift toward the easiest protocols and sites.

A retainer plus media pass-through model pays the vendor a fixed fee for labor, with media spend passing through separately. Nothing ties spend to outcomes, so a retainer can run for months with little to show unless reporting is tight.

Platform subscription or license pricing charges for access rather than output: a flat or tiered fee to query the platform. The risk shows up in rare indications, where a sponsor can pay for a year of access and get almost nothing back.

Most contracts are hybrids. Read a blended quote by splitting the fixed part from the variable, then ask what event triggers each. No peer-reviewed or regulatory source publishes vendor price benchmarks [2]. Whichever model applies, check one clause: does the fee event survive a participant's later dropout?

What a vendor can fix, and what it cannot

Structural barriers explain more of the enrollment gap than any vendor decision does. One review pooled 13 studies and 8,883 cancer patients: a trial was unavailable at the patient's own institution 55.6% of the time, 21.5% of patients were ineligible, and overall enrollment reached 8.1% [3]. More than half of that loss happens before a vendor is hired.

Site capacity is the second structural limit: in a 2024 survey of 852 research sites, 46% said their top challenges restrict their capacity to take on new studies [4]. Eligibility criteria are the third: across 1,286 industry-sponsored phase 2 and 3 trials, the number of inclusion criteria was one of three protocol-design factors tied to longer enrollment [9].

What a vendor does fix is reach and throughput inside those limits. 51% of people would prefer to hear about a trial from their own doctor; only 8% did [5]. A vendor's media and prescreen throughput close part of that gap, getting a plausibly eligible person to a site faster than word of mouth would.

Which recruitment tactics have evidence behind them

A Cochrane review of 72 recruitment comparisons found only three backed by high-certainty evidence: open rather than blinded placebo designs and telephone reminders to postal non-responders raise recruitment, while a bespoke way of developing participant information leaflets made little or no difference [10].

A meta-analysis comparing online and offline recruitment found online channels faster and cheaper per enrollee at US $72 against US $199, but offline recruitment converted better in most studies that measured conversion [12].

The Clinical Trials Transformation Initiative's recruitment planning framework makes the structural point: plan recruitment at protocol design, because eligibility criteria and site choice shape the problem more than any later campaign can fix [13].

The obligations that never transfer with the contract

A sponsor can transfer specific obligations to a CRO in writing under 21 CFR 312.52, but any obligation the transfer document does not name stays with the sponsor [14]. Patient recruitment agencies typically assume none of those obligations. The FDA treats recruitment advertising as the start of the informed consent process and requires IRB review before the ad runs [8].

A vendor that sees identifiable patient data needs a named HIPAA pathway: individual authorization, a waiver, the preparatory-to-research allowance, or a business associate arrangement with a covered entity [16]. ICH E6(R3), which FDA issued as final guidance in September 2025, is explicit: a sponsor may transfer trial-related activities to a service provider, but ultimate responsibility for participant protection and data reliability stays with the sponsor [17].

Delegating recruitment to a vendor does not delegate the sponsor's oversight. None of this is legal advice; confirm every obligation with regulatory counsel and the IRB of record before signing.

Three numbers to stop repeating

"80% of clinical trials fail to meet enrollment timelines." This figure runs across vendor blogs with no primary citation. Among 2,542 randomized surgical trials, 79.6% finished outside their planned timeframe and 54.1% missed their enrollment target [19]. Late is not failed, and one surgical cohort is not every trial.

"Each day of delay costs $600,000 to $8 million." That range dates to early-2000s industry estimates repeated without a source. The current measured figure: roughly $500,000 in lost sales plus $40,000 in direct trial costs per day [2].

"Only 3% to 5% of patients participate in clinical trials." This is an oncology-era estimate applied to every trial. The measured figure in cancer settings is 8.1% enrollment across 13 studies, and in 55.6% of cases no trial was available to the patient at all [3]. What gets quoted as a participation rate is mostly an availability rate.

How to choose a patient recruitment vendor: four contract checks

Refero's recruitment benchmarks guide holds the performance questions to ask before these contract checks. Those settle whether a vendor can perform. These four establish what you are signing.

1. Which event triggers a fee: referral, prescreen pass, consent, or randomization? The fee event is the incentive, and a vendor paid per referral gets paid before the site has confirmed the referral was worth having.

2. Who owns the ad accounts, creative, landing pages, phone numbers, and referral data when the contract ends? A sponsor that cannot take its campaign assets to a second vendor is not switching vendors; it is starting again from zero.

3. Who submits recruitment materials to the IRB of record, and does anything run before that approval comes back? The IRB review obligation belongs to the sponsor and the investigator, whoever drafted the ad.

4. Under which HIPAA pathway does the vendor receive identifiable information, and will it sign a business associate agreement where one is required? The answer decides whether the vendor may legally touch site data.

If you would rather not run that evaluation alone, Refero screens healthcare marketing and patient recruitment agencies against five published criteria and introduces up to three that fit your brief. It is free for buyers, and there is no obligation to hire anyone we introduce. Tell us what you need.

Frequently asked questions

What is a patient recruitment vendor?

A patient recruitment vendor finds, prescreens, and refers potential participants to research sites for a clinical trial, under contract to a sponsor, CRO, or site. It does not recruit clinical research staff, and it is not the sponsor's CRO unless recruitment is bundled into a CRO contract.

What types of patient recruitment vendors are there?

There are six main types, sorted by the part of the enrollment funnel each owns: site-network recruiters, central recruitment and media agencies, patient registry and database platforms, EHR and data-driven identification services, decentralized trial and eConsent platforms with recruitment modules, and CRO-bundled recruitment.

How do patient recruitment vendors charge?

Under four models. Per-referral or per-lead fees reward volume. Per-milestone or per-randomized fees reward qualification. A retainer plus media pass-through rewards time and shows media cost separately. Platform subscriptions reward breadth of access. No independent source publishes vendor price benchmarks.

What is the difference between a patient recruitment company and a CRO?

A CRO is contracted to run part or all of a trial, and a sponsor can transfer specific obligations to it in writing under 21 CFR 312.52 [14]. A patient recruitment company is contracted for one task: finding and referring participants. It is typically not a CRO under that section, so sponsor obligations stay with the sponsor.

How do you evaluate a patient recruitment vendor?

Run two sets of questions in order. First, the performance questions in Refero's recruitment benchmarks guide, which test whether the vendor can deliver in your indication. Second, the four contract checks in this guide: the fee event, asset ownership, IRB submission, and the HIPAA pathway.

Sources

• Williams RJ, Tse T, DiPiazza K, Zarin DA. Terminated Trials in the ClinicalTrials.gov Results Database: Evaluation of Availability of Primary Outcome Data and Reasons for Termination. PLoS One, 2015. Link
• Smith ZP, DiMasi JA, Getz KA. New Estimates on the Cost of a Delay Day in Drug Development. Therapeutic Innovation and Regulatory Science, 2024. Link
• Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation. Journal of the National Cancer Institute, 2019. Link
• WCG Clinical. 2024 Clinical Research Site Challenges Report. Link
• CISCRP. 2025 Perceptions and Insights Study. Link
• Walters SJ, et al. Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme. BMJ Open, 2017. Link
• Kasenda B, et al. Prevalence, Characteristics, and Publication of Discontinued Randomized Trials. JAMA, 2014. Link
• US Food and Drug Administration. Recruiting Study Subjects: Information Sheet. Link
• Tsuchiya H, et al. Association of Protocol Design-Related Factors With Enrollment Duration in Clinical Trials. Clinical and Translational Science, 2026. Link
• Treweek S, et al. Strategies to improve recruitment to randomised trials. Cochrane Database of Systematic Reviews, 2018. Link
• Frampton GK, Shepherd J, Pickett K, Griffiths G, Wyatt JC. Digital tools for the recruitment and retention of participants in randomised controlled trials: a systematic map. Trials, 2020. Link
• Brøgger-Mikkelsen M, Ali Z, Zibert JR, Andersen AD, Thomsen SF. Online Patient Recruitment in Clinical Trials: Systematic Review and Meta-Analysis. Journal of Medical Internet Research, 2020. Link
• Huang GD, et al. Clinical trials recruitment planning: A proposed framework from the Clinical Trials Transformation Initiative. Contemporary Clinical Trials, 2018. Link
• 21 CFR 312.52, Transfer of obligations to a contract research organization. eCFR. Link
• 21 CFR 50.20, General requirements for informed consent. eCFR. Link
• 45 CFR 164.512(i), 164.508, and 164.502(e). eCFR. Link
• US Food and Drug Administration. E6(R3) Good Clinical Practice (GCP), final guidance, September 2025, section 3.6.6. Link
• Getz KA. Enrollment Performance: Weighing the "Facts". Applied Clinical Trials, 2012. Link
• Shadbolt C, et al. Analysis of Rates of Completion, Delays, and Participant Recruitment in Randomized Clinical Trials in Surgery. JAMA Network Open, 2023. Link